A Novel Multiplex ELISA Assay for Surveilling Patients With History of Bladder Cancer

Inclusion Criteria Participants must be: * Age 18 years or older * Have a history of non-muscle invasive bladder cancer or muscle invasive bladder cancer treated by bladder sparing techniques (or not yet treated) and diagnosed within the past 24 months on cystoscopic surveillance * Participants may be treated with adjuvant intravesical therapy * Willing and able to give written informed consent (see Appendix 1) * Be willing to adhere to the surveillance regimen (high risk and intermediate risk seen every 3 months for 2 years; low risk seen every 6-12 months for 2 years) Exclusion Criteria: Participants must not: * Have had radical cystectomy * History of previous cancer (excluding bladder, basal and squamous cell skin cancer) within the past 3 years * Have a known active urinary tract infection or urinary retention * Have active stone disease (renal or bladder) or renal insufficiency (creatinine \>2.0 mg/dL) - Serum creatinine value can be up to 60 days before consent, otherwise repeat. * Have ureteral stents, nephrostomy tubes or bowel interposition * Have recent genitourinary instrumentation (within 10 days prior to signing consent) * Be unable or unwilling to complete the surveillance regimen